SCHEMBL5037465

SCHEMBL5037465

COC(C(=O)NCc1ccc(C#N)cc1)c1c(F)cccc1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.47
CNR2 P34972 1/20 0.46
BACE1 P56817 2/20 0.44
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
HTR1A P08908 4/20 0.41
DRD2 P14416 4/20 0.41
HTR7 P34969 4/20 0.41
HTR6 P50406 4/20 0.41
HTR2A P28223 1/20 0.41
HTR5A P47898 1/20 0.41
HIF1A Q16665 1/20 0.41
SCN9A Q15858 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SCN5A Q14524 1/20 0.39
PDCD1 Q15116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037467 1.00 PKM (0.47) PKMCNR2BACE1SLC1A3SLC1A2
SCHEMBL5041552 0.90 PKM (0.48) PKMSLC1A3SLC1A2HIF1ASCN9A
SCHEMBL5041550 0.90 PKM (0.48) PKMSLC1A3SLC1A2HIF1ASCN9A
SCHEMBL5040804 0.86 PKM (0.48) PKMCNR2BACE1SLC1A3SLC1A2
SCHEMBL5040802 0.86 PKM (0.48) PKMCNR2BACE1SLC1A3SLC1A2
SCHEMBL5042039 0.85 PKM (0.45) PKMSLC1A3SLC1A2HIF1ASCN9A
SCHEMBL5042034 0.85 PKM (0.45) PKMSLC1A3SLC1A2HIF1ASCN9A
SCHEMBL5040796 0.85 PKM (0.41) PKMCNR2SLC1A3SLC1A2HTR1A
SCHEMBL5042636 0.85 HIF1A (0.46) PKMSLC1A3SLC1A2HTR1ADRD2
SCHEMBL5042640 0.85 HIF1A (0.46) PKMSLC1A3SLC1A2HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 PKM 4225/4885CNR2 372/4885BACE1 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.